Parabilis Q2 net loss $52.5M; $1.1B cash after $770.5M IPO; Regeneron deal up to $2.2B

Parabilis Medicines, Inc.

Net loss $52.5M in Q2 2026 vs $34.8M prior year; R&D $39.4M, G&A $11.7M.
Cash $1.1B as of June 30, 2026 (vs $27.7M Dec 31, 2025) after $770.5M IPO at $20.00/share; funds ops into 2030.
Regeneron collaboration: $125M received ($50M upfront + $75M equity); up to $2.2B milestones plus low double-digit tiered royalties for Antibody-Helicon Conjugates.
Zolucatetide: ESMO 2026 abstract accepted; FDA alignment Q4 2026; Phase 3 desmoid trial initiation H1 2027; FAP cohort H2 2026.
Leadership: Helen Ho (Chief Business & Strategy Officer), Tom Kotarakos (CFO), Alan M. Sebulsky to Board.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.